カテゴリ： GlobalData, アメリカ, 企業調査

Iovance Biotherapeutics Inc (IOVA)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Iovance Biotherapeutics Inc (IOVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9991
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：81
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating lymphocyte (TIL) technology. The company’s lead product candidate, LN-144 is an autologous, ready-to-infuse cell therapy. The product is an adoptive cell therapy using TIL technology and is being investigated in Phase II trials for the treatment of patients with metastatic melanoma, recurrent and metastatic squamous cell carcinoma of the neck and head and recurrent and metastatic or persistent cervical cancer. The company operates a research facility in Tampa, Florida. Iovance is headquartered in San Carlos, California, the US.

Iovance Biotherapeutics Inc (IOVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Private Equity 12
Lion Biotechnologies Raises USD100 Million in Financing 12
Partnerships 14
RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 14
Iovance Biotherapeutics Enters into Research Agreement with Arthur G. James Cancer Hospital & Richard J Solove Research Institute 15
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 16
Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 17
Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 18
Lion Biotech Enters into Research Agreement with MedImmune 19
Lion Biotech Enters into Agreement with WuXi AppTec 20
Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 21
Merger 22
Genesis Biopharma And Lion Biotech Merge 22
Licensing Agreements 23
Lion Biotechnologies Enters into Licensing Agreement with PolyBioCept 23
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 24
Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 25
Equity Offering 26
Iovance Biotherapeutics Raises USD252.2 Million in Public Offering of Shares 26
Iovance Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 27
Iovance Biotherapeutics Raises USD57.5 Million in Public Offering of Shares 29
Lion Biotechnologies Raises USD47.5 Million in Public Offering of Shares 31
Lion Biotech Raises USD73.6 Million in Public Offering of Shares 32
Lion Biotech Raises USD34.5 Million in Public Offering of Shares 34
Lion Biotech Completes Private Placement Of Units For US$23.3 Million 36
Genesis Biopharma Completes Private Placement Of Shares For US$1.1 Million 38
Iovance Biotherapeutics Inc – Key Competitors 39
Iovance Biotherapeutics Inc – Key Employees 40
Iovance Biotherapeutics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 06, 2018: Iovance Biotherapeutics reports third quarter 2018 financial results and provides corporate update 42
Aug 06, 2018: Iovance Biotherapeutics reports second quarter 2018 financial results and provides corporate update 45
May 10, 2018: Iovance Biotherapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 47
Mar 12, 2018: Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update 49
Oct 31, 2017: Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results 51
Aug 01, 2017: Iovance Biotherapeutics Reports Second Quarter 2017 Financial Results 54
May 01, 2017: Lion Biotechnologies Reports First Quarter 2017 Financial Results 56
Mar 07, 2017: Lion Biotechnologies Reports Fourth Quarter and Full-Year 2016 Financial Results and Provides Corporate Update 58
Corporate Communications 60
Mar 01, 2018: Iovance Biotherapeutics Appoints Michael Weiser, M.D., Ph.D., to its Board of Directors 60
Aug 08, 2017: Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer 61
May 25, 2017: Lion Biotechnologies Announces Departure of Chief Financial Officer 62
Product Approvals 63
Aug 31, 2017: Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma 63
Clinical Trials 64
Jun 07, 2018: Iovance Biotherapeutics Announces First Patient Dosed in Europe for Ongoing C-144-01 Phase 2 Trials in Metastatic Melanoma 64
Jan 24, 2018: Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers 65
Nov 09, 2017: Iovance Biotherapeutics Announces New LN-144 Phase 2 Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting 66
Nov 09, 2017: Iovance Biotherapeutics Announces Presentation on Its cancer Drug candidate LN-145 at SITC Meeting 68
Oct 11, 2017: Iovance Biotherapeutics to Present Abstracts on Tumor-infiltrating Lymphocyte Therapy (LN-144) at 2017 SITC Annual Meeting 69
Oct 11, 2017: Iovance Biotherapeutics to Present Abstracts on Tumor-infiltrating Lymphocyte Therapy (LN-145) at 2017 SITC Annual Meeting 70
Sep 13, 2017: Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer 71
Aug 16, 2017: Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer 72
Jun 05, 2017: Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial 73
Jun 01, 2017: Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer 74
May 19, 2017: Lion Biotechnologies Announces First Patient Dosed in Second Cohort of LN-144 Phase 2 Trial for Metastatic Melanoma 75
May 17, 2017: Lion Biotechnologies to Present New Data from Ongoing LN-144 Phase 2 Clinical Trial at 2017 American Society of Clinical Oncology Annual Meeting 76
Apr 18, 2017: Lion Biotechnologies Highlights Publication of New Translational Data in Science for TIL Therapy for Treatment of Cervical Cancer 77
Other Significant Developments 78
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 78
Dec 13, 2017: Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017 79
Jun 27, 2017: Lion Biotechnologies Changes Name to Iovance Biotherapeutics 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81

List of Tables
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Iovance Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lion Biotechnologies Raises USD100 Million in Financing 12
RXi Pharma Enters into Research Collaboration with Iovance Biotherapeutics 14
Iovance Biotherapeutics Enters into Research Agreement with Arthur G. James Cancer Hospital & Richard J Solove Research Institute 15
Lion Biotech Enters into Agreement with MD Anderson Cancer Center 16
Lion Biotechnologies Enters into Research Agreement with H. Lee Moffitt Cancer Center and Research Institute 17
Lion Biotechnologies Enters into Clinical Trial Agreement with Karolinska University Hospital 18
Lion Biotech Enters into Research Agreement with MedImmune 19
Lion Biotech Enters into Agreement with WuXi AppTec 20
Lion Biotech Enters into Research Agreement with Lee Moffitt Cancer Center and Research Institute 21
Genesis Biopharma And Lion Biotech Merge 22
Lion Biotechnologies Enters into Licensing Agreement with PolyBioCept 23
Lion Biotech Enters into Licensing Agreement with National Institutes of Health 24
Lion Biotech Enters into Licensing Agreement wih Moffitt Cancer Center 25
Iovance Biotherapeutics Raises USD252.2 Million in Public Offering of Shares 26
Iovance Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 27
Iovance Biotherapeutics Raises USD57.5 Million in Public Offering of Shares 29
Lion Biotechnologies Raises USD47.5 Million in Public Offering of Shares 31
Lion Biotech Raises USD73.6 Million in Public Offering of Shares 32
Lion Biotech Raises USD34.5 Million in Public Offering of Shares 34
Lion Biotech Completes Private Placement Of Units For US$23.3 Million 36
Genesis Biopharma Completes Private Placement Of Shares For US$1.1 Million 38
Iovance Biotherapeutics Inc, Key Competitors 39
Iovance Biotherapeutics Inc, Key Employees 40
Iovance Biotherapeutics Inc, Other Locations 41
Iovance Biotherapeutics Inc, Subsidiaries 41

List of Figures
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Iovance Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Iovance Biotherapeutics Inc (IOVA)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Ryoden Trading Co Ltd：企業の戦略・SWOT・財務情報
    Ryoden Trading Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Ryoden Trading Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Carlsberg AS (CARL B)：企業の財務・戦略的SWOT分析
    Carlsberg AS (CARL B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lincoln Pharmaceuticals Ltd (LINCOLN)：企業の財務・戦略的SWOT分析
    Lincoln Pharmaceuticals Ltd (LINCOLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • SES SA (SESG)：企業の財務・戦略的SWOT分析
    SES SA (SESG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • AGCO Corporation：企業の戦略・SWOT・財務情報
    AGCO Corporation - Strategy, SWOT and Corporate Finance Report Summary AGCO Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Amgen Inc (AMGN)-製薬・医療分野：企業M&A・提携分析
    Summary Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncol …
  • Caixa Economica Federal
    Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Siem Offshore Inc (SIOFF)：企業の財務・戦略的SWOT分析
    Summary Siem Offshore Inc (Siem Offshore), a subsidiary of Siem Industries Inc is a marine service provider that owns and operates modern offshore support vessels for the offshore oil and gas industries. The company offers shipbuilding, ordering and delivery of new vessels, acquisition of modern sec …
  • Shopping Centres Australasia Property Group RE Limited：企業の戦略・SWOT・財務情報
    Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report Summary Shopping Centres Australasia Property Group RE Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Goodman Co Ltd-医療機器分野：企業M&A・提携分析
    Summary Goodman Co Ltd (Goodman), a subsidiary of Nipro Corp is a medical device company that develops, manufactures and distributes medical equipment and medical disposables. The company’s products include scoring equipment, semi-compliant systems, non-compliant systems, aspiration catheters, devic …
  • Kubota Corporation (6326)：企業の財務・戦略的SWOT分析
    Kubota Corporation (6326) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Hooker Furniture Corporation (HOFT)：企業の財務・戦略的SWOT分析
    Hooker Furniture Corporation (HOFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dev Information Technology Limited (DEVIT)：企業の財務・戦略的SWOT分析
    Dev Information Technology Limited (DEVIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Faron Pharmaceuticals Oy (FARN)：企業の財務・戦略的SWOT分析
    Summary Faron Pharmaceuticals Oy (Faron) is a clinical stage biopharmaceutical company that develops treatments for unmet medical needs. The company is developing pipeline products with a focus on vascular damage, acute organ traumas and cancer immunotherapy. It offers Clevegen, a humanized Clever-1 …
  • aTyr Pharma Inc (LIFE)：製薬・医療：M&Aディール及び事業提携情報
    Summary ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company’s ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to th …
  • Natcore Technology Inc (NXT)：電力：M&Aディール及び事業提携情報
    Summary Natcore Technology Inc (Natcore) is a solar research and development company that provides products for semiconductor and fiber optic applications. The company’s products include solar cell structures and black silicon cells. It uses liquid phase deposition technology for controlling deposit …
  • Asahi Kasei Corporation：企業の戦略・SWOT・財務情報
    Asahi Kasei Corporation - Strategy, SWOT and Corporate Finance Report Summary Asahi Kasei Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • China National Petroleum Corporation：企業の戦略・SWOT・財務分析
    China National Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary China National Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • AEON Credit Service (Asia) Co., Ltd.：企業の戦略・SWOT・財務情報
    AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AEON Credit Service (Asia) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Ampcontrol Pty Ltd：企業の戦略・SWOT・財務情報
    Ampcontrol Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Ampcontrol Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆